Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Colorectal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 5 · 62.5%High 2 · 25%

Severe adverse effects · people with metastatic CRC

Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.07 [0.93, 1.25]
4 studies · 1708 participants
Low

Severe adverse effects · people with metastatic CRC

Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.19 [1.01, 1.4]
1 study · 279 participants
Moderate

Severe adverse effects · people with metastatic CRC

FOLFOX + targeted therapy leads to higher severe adverse effects compared with FOLFOX (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.2 [1.13, 1.28]
2 studies · 1414 participants
High

Severe adverse effects · people with metastatic CRC

FOLFIRI + targeted therapy probably leads to higher severe adverse effects compared with FOLFIRI (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.3 [1.17, 1.45]
6 studies · 3341 participants
Moderate

Severe adverse effects · people with metastatic CRC

Modern chemotherapy regimens probably leads to higher severe adverse effects compared with 5‐flourouracil (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.39 [1.22, 1.58]
3 studies · 843 participants
Moderate

Severe adverse effects · people with metastatic CRC

Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.44 [1.31, 1.59]
2 studies · 1704 participants
High

Severe adverse effects · people with metastatic CRC

Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.18 [0.96, 1.45]
6 studies · 2510 participants
Moderate

Severe adverse effects · people with metastatic CRC

Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.22 [1.09, 1.37]
1 study · 627 participants
Moderate